The Cardiac Surgery team at Castle Hill Hospital is among the leading centres recruiting patients for the AFFECT trial. This study, funded by the National Institute for Health and Care Research, involves over 30 centres across the UK and is spearheaded by researchers at The James Cook University Hospital in Middlesbrough.
The trial aims to address a crucial question regarding the safest and most effective blood-thinning medication for patients who have undergone mitral valve repair surgery and also experience heart rhythm problems. Benjamin Omoregbee, Locum Consultant Cardiac Surgeon at Castle Hill Hospital and Principal Investigator for the trial in Hull, stated, “We are one of the leading recruiting sites in the UK and it is fantastic for Hull patients to have the opportunity to take part in this important national research.”
He added, “The trial is trying to answer a fundamental question around anticoagulation and help establish which medication is best for patients going forward. By recruiting patients here in Hull, we are contributing to the evidence that could help guide future treatment.” The study plans to enrol 1,282 adults undergoing mitral valve repair surgery at cardiothoracic centres nationwide. Participants will be randomly assigned either a Direct Oral Anticoagulant (DOAC) or a vitamin K antagonist (VKA), such as warfarin.
Researchers will evaluate outcomes including stroke prevention, quality of life, and cost-effectiveness. Nationally, over 130 patients have already joined the trial and commenced treatment. Professor Enoch Akowuah, chief investigator for the AFFECT trial, commented, “The AFFECT Trial will provide high-quality evidence to guide national treatment decisions and improve long-term outcomes for patients across the UK and internationally.” Eligible patients will be approached by their clinical teams. Those interested can also speak to their care team.
